Overspending driven by oversized single dose vials of cancer drugs
- PMID: 26932932
- PMCID: PMC6894487
- DOI: 10.1136/bmj.i788
Overspending driven by oversized single dose vials of cancer drugs
Abstract
Peter B Bach and colleagues call for an end to contradictory regulatory standards in the US that allow drug manufacturers to boost profits by producing single dose vials containing quantities that increase leftover drug
Conflict of interest statement
Competing Interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: PBB reports personal fees from Association of Community Cancer Centers, America's Health Insurance Plans, AIM Specialty Health, American College of Chest Physicians, American Society of Clinical Oncology, Barclays, Defined Health, Express Scripts, Genentech, Goldman Sachs, McKinsey and Company, MPM Capital, National Comprehensive Cancer Network, Novartis, Biotechnology Industry Organization,
Figures
Comment in
-
The drug industry can help reduce cancer drug costs.BMJ. 2016 Mar 21;352:i1551. doi: 10.1136/bmj.i1551. BMJ. 2016. PMID: 27001595 No abstract available.
References
-
- Lien K, Cheung MC, Chan KK. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract 2015 . Sep 1 JOP.2015.005876. - PubMed
-
- Smith RS. A 2-year retrospective review of vial sharing options for the compounding of cytotoxics. Eur J Hosp Pharm 2015;22:161-4 10.1136/ejhpharm-2014-000547. . - DOI
-
- United States Pharmacopeia, ed. USP< 797> Guidebook to pharmaceutical compounding-sterile preparations.United States Pharmacopeial Convention, 2008.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous